

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 38/09, 38/25, 47/22</b>		A1	(11) International Publication Number: <b>WO 98/53844</b> (43) International Publication Date: 3 December 1998 (03.12.98)
(21) International Application Number:	PCT/EP98/03079	(81) Designated States:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	26 May 1998 (26.05.98)	(30) Priority Data:	
97108593.1	28 May 1997 (28.05.97)	EP	
(34) Countries for which the regional or international application was filed:	AT et al.		
97121246.9	3 December 1997 (03.12.97)	EP	
(34) Countries for which the regional or international application was filed:	AT et al.		
(71) Applicant (for all designated States except US):	APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. [NL/NL]; John B. Gorsiraweg 14, Curacao (AN).	Published	<i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventor; and			
(75) Inventor/Applicant (for US only):	RICHARDSON, Peter [GB/GB]; 38 Manor Drive, Epsom, Surrey KT19 0ET (GB).		
(74) Agent:	VANNINI, Mario; Istituto Farmacologico Serono S.p.A., Via Casilina, 125, I-00176 Rome (IT).		

**(54) Title:** PHARMACEUTICAL COMPOSITIONS OF PEPTIDES HAVING LOW SOLUBILITY IN PHYSIOLOGICAL MEDIUM**(57) Abstract**

Pharmaceutical compositions are described, which comprise: a) a peptide poorly soluble in aqueous physiological saline solution, as active ingredient; b) a non-ionic aromatic hydrotropic pharmaceutically acceptable agent; and c) a physiological aqueous solution wherein the peptide (a) is an LHRH analogue or a GRF peptide, and wherein the non-ionic aromatic hydrotropic agent (2) is selected from the group consisting of: nicotinamide, nicotinic acid, benzoic acid, salicyclic acid, gentisic acid, ascorbic acid, histidine, tryptophan, phenylalanine, tyrosine, cresol, phenol, xanthines, pyridoxine, folic acid, saccharin, as well as non-ionic derivatives thereof.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

-1-

**PHARMACEUTICAL COMPOSITIONS OF PEPTIDES HAVING LOW  
SOLUBILITY IN PHYSIOLOGICAL MEDIUM**

**FIELD OF THE INVENTION**

5        The present invention relates to a pharmaceutical composition comprising:

- a) a peptide poorly soluble in aqueous physiological saline solution, as active ingredient;
- b) a non-ionic aromatic hydrotropic pharmaceutically acceptable agent; and
- c) a physiological aqueous solution.

10      According to a preferred embodiment of the invention, the peptide (a) is an LHRH analogue or a GRF peptide.

**BACKGROUND OF THE INVENTION**

It is often necessary to improve the solubility of a drug in physiological media in order to achieve effective clinical performance of injectable formulations of the drug.

15      Peptide drugs are often poorly soluble in physiological media due to the presence of hydrophobic substituents.

Solubility problems can also lead to poor absorption by other routes of administration and in some cases suitable solubilising agents can aid the absorption of the drug by other routes, for example oral or nasal.

20      Exemplary peptide drugs that are so poorly soluble in physiological media are LHRH analogues and growth hormone releasing factor (GRF) peptides.

25      Luteinising hormone releasing hormone (LHRH or GnRH) is a decapeptide secreted by hypothalamus and capable of inducing the release of both LH and FSH. It has the following formula: pyroGlu - His - Trp - Ser - Tyr - Gly - Leu - Arg - Pro - Gly - NH<sub>2</sub>.

30      LHRH can either stimulate pituitary gonadotropin secretion or be a potent inhibitor. When administered in a precise pulsatile pattern LHRH can restore the normal cyclic gonadotropin secretion. Pulsatile administration of LHRH using a computerized pump was used with good results in the induction of ovulation in anovulatory women with hypothalamic dysfunction. When administered chronically, LHRH or its agonists

-2-

proved to be potent inhibitors of gonadotropic secretion, providing a temporary (fully reversible) gonadotropin specific medical hypophisectomy.

To date, thousands of LHRH analogs have been synthesized, that can act either as agonists or antagonists. In order to produce LHRH antagonists, which work by receptor occupancy, it is necessary to substitute several amino acids on the LHRH molecule. Antagonists also require precise topological features to achieve high binding affinity to the receptor. There are a lot of LHRH analogues recently synthesized, in which the amino acids contain aromatic or other functional groups capable of the so-called hydrotropic interaction. The use of LHRH antagonists with their immediate inhibition of gonadotrophin release may be useful in therapeutic areas, such as contraception and in treatment of hormone-dependent disorders. In the case of hormone-dependent tumors, avoiding the initial stimulatory phase produced by LHRH agonists may be a particular advantage. For a review on LHRH analogues, see Kartan and Rivier, 1986.

Antide, in particular, is a potent LHRH antagonist, with formula, biological activity and preparation as described in EP Patent 377,665.

From studies carried out by the Applicant, it resulted, for example, that antide has a very poor solubility in 0.9% NaCl solution (solubility 25 µg/ml) or other isotonic media such as phosphate buffered saline (solubility was 16 µg/ml). Previous aqueous formulations of antide have shown poor bioavailability and pharmacokinetic reproducibility. This is due to antide being present at the site of injection in concentrations above 25 µg/ml for example, which leads to the formation of a precipitate on contact with the physiological medium. This precipitate can be gelatinous in nature and has a detrimental effect on drug absorption, as shown by clinical investigations carried out by the Applicant.

Other gonadotrophin releasing hormone antagonists in aqueous solutions can form gel structures and in addition, the solubility is known to increase as the pH of the solution is reduced, due to increased ionisation of the molecule (Cannon J.B, et al., 1995).

GRF (also called Somatorelin) is a peptide secreted by the hypothalamus which promotes the release of growth hormone from the anterior pituitary. It occurs naturally

-3-

as 44-, 40-, and 37-amino acid peptides; the 44-amino acids form may possibly be converted into smaller forms, but all are reported to be active, the activity residing in the first 29 amino acid residues. A peptide corresponding to the 1-29 amino acid sequence of human GRF [hGRF(1-29)], also called Sermorelin, has been prepared by recombinant DNA technology as described in European Patent EP 105 759.

5 Sermorelin has been used in the form of acetate for the diagnosis and treatment of growth hormone deficiency.

GRF has a therapeutic value for the treatment of certain growth-hormone related disorders. The use of GRF to stimulate the release of GH is a physiologic method of 10 inducing long bone growth or protein anabolism.

It is well known that the natural form of GRF can suffer from chemical degradation in aqueous solution, primarily of Asn at position 8 which results in reduced biological potency (Friedman et al., 1991; Bongers et al., 1992).

15 The main hydrolytic reactions occurring in GRF are sensitive to pH and reported to be: rearrangement of Asp<sup>3</sup>, at pH 4-6.5, cleavage of the Asp<sup>3</sup>-Ala<sup>4</sup> bond at pH 2.5-4.5, deamidation and rearrangement of Asn<sup>8</sup> at pH above 7 (Felix A.M., 1991). Due to the combined degradation pathways, unstabilised aqueous solutions GRF are most stable in the pH range 4-5. Bongers et al. (Bongers et al., 1992) have shown that the deamidation reaction at Asn<sup>8</sup> increases rapidly as the pH is raised above pH 3.

20 Various workers have made analogues of GRF by substitution of amino acids into the natural GRF sequence to improve the chemical stability (Serono Symposia USA, 1996; Friedman, 1991). While modification can be an effective means to improve the stability and retain bioactivity, it may be undesirable due to altered immunogenicity, which could be a problem for chronic therapies such as growth hormone deficiency.

25 It is known from the literature that, in certain cases, the addition of aromatic agents to solutions of proteins can cause a negative effect on solubility, resulting in precipitation. For example, when aromatic agents were brought into contact with recombinant human growth hormone (rhGH), conformational changes or denaturation occurred, resulting in the formation of rhGH aggregates. (Maa Y.F. and Hsu C.C., 30 1996). Additionally, to show that this was not a general phenomenon, it was shown that

-4-

aromatic amino acid derivatives improved the solubility and enhanced the absorption of growth hormone (Leone Bay A, et al., 1996).

Nicotinamide has been reported to solubilise conventional pharmaceutical compounds (i.e. non-peptides with molecular weight less than 1000 daltons) by a process of charge transfer complexation, also called hydrotropic solubilisation. This process may result from the interaction of aromatic groups in the solubilising agent and aromatic or other suitable functional groups on the drug molecule. For example see Rasool et al., 1991.

However, the Applicant has found, and the corresponding data are here reported in the experimental section, that other molecules, containing aromatic groups such as benzoate or salicylate, which could interact by a hydrotropic mechanism (Jain N.K. and Patel V.V., 1986), show only a minor improvement in the solubilisation of an LHRH analogue (antide) in saline solution.

European Patent Application 0 649 655 describes the solubilisation of a water insoluble anti-ulcer drug using nicotinamide in order to produce a useful injectable form. Many potential derivatives of the active moiety are claimed, however, no in-vivo data were presented to demonstrate improved efficacy.

PCT Application WO 96/10417 describes the co-administration of Asp<sup>B28</sup> human insulin and nicotinamide in order to achieve a rapid onset of action of the hypoglycaemic effect. The claimed nicotinamide concentration range was 0.01 to 1 M (0.1-12% w/w), but preferably from 0.05 to 0.5 M. The document gives evidence for faster absorption during an in-vivo study in pigs, however, a mechanism by which the improved absorption occurs is not addressed and, therefore, no generalisable teachings can be drawn from this document.

25

#### DESCRIPTION OF THE INVENTION

It has been found that when a non-ionic aromatic hydrotropic agent is added to aqueous solutions of a peptide drug, which is normally poorly soluble in aqueous physiological saline solution, its solubility is increased and the resulting pharmaceutical compositions also show excellent stability.

-5-

In particular, it has been found that when nicotinamide is added to a saline solution (0.9% NaCl) of antide, the molecule can promote the solubility of this drug. The final concentration of antide solubilised is dependent on the concentration of nicotinamide added and increases exponentially with increased nicotinamide 5 concentration, as shown below. The solubility of the gonadotrophin releasing hormone antagonists is known to increase as the pH of the solution is reduced, however, the data reported here in the experimental section for antide show that the increased solubility is not due to a pH effect. In addition, it has been found that nicotinamide can also increase the solubility of antide in purely aqueous environments.

10 Therefore, the main object of the present invention is to provide a pharmaceutical composition comprising:

- a) a peptide poorly soluble in aqueous physiological saline solution, as active ingredient;
- b) a non-ionic aromatic hydrotropic pharmaceutically acceptable agent; and
- c) a physiological aqueous solution.

15 The peptide active ingredient can be an LHRH analogue or a growth hormone releasing factor (GRF) peptide. Preferably, the LHRH analogue is an antagonist. More preferably, it is antide, hGRF or PEG-conjugates thereof.

According to this invention the word "hGRF" is intended to cover any human 20 GRF peptide, with particular reference to the 1-44, 1-40, 1-29 peptides and the corresponding amides thereof (containing -NH<sub>2</sub> at their end). They are all commercial compounds. The preferred hGRF is hGRF(1-29)-NH<sub>2</sub>. The GRF peptide used in the Examples will be the commercial product specified in the "Materials" paragraph.

It has also been discovered that the addition of nicotinamide to aqueous solutions 25 of hGRF can reduce the rate of deamidation of Asn<sup>8</sup> and of additional degradation products, not all of which have been identified at the present time. It is known that Asn<sup>8</sup> can degrade in aqueous solution to form the following degradation products:  $\alpha$ -Asp<sup>8</sup>,  $\beta$ -Asp<sup>8</sup> and succinimidyl-Asn<sup>8</sup>.

It has also been discovered that GRF can be dissolved in non-aqueous solvents 30 and by the consequent reduction of the activity of water in the solution, deamidation at position Asn<sup>8</sup> is prevented. When the GRF is dissolved in propylene glycol (PG), it was found that alternative (not fully characterised) degradation pathways occur. It has also

-6-

been found that by incorporating nicotinamide into non-aqueous solution such as PG, the rate of formation of some of these additional degradation products is reduced.

A non-limiting list of suitable pharmaceutically acceptable non-ionic aromatic hydrotropic agents comprises: nicotinamide, nicotinic acid, benzoic acid, salicylic acid, gentisic acid, ascorbic acid, histidine, tryptophan, phenylalanine, tyrosine, cresol, phenol, xanthines, pyridoxine, folic acid, saccharin. Non-ionic derivatives of any of the above compounds would also be applicable for the purposes of this invention. Nicotinamide is the preferred one.

Nicotinamide is a commonly used source of vitamin B in pharmaceutical products and is administered mainly by the oral route, but also by injection. Doses of up to 500 mg daily (in divided doses) have been recommended, e.g. see Martindale.

The physiological aqueous solution can be isotonic saline or phosphate buffered saline or any suitable solution containing inorganic salts at the same tonicity as the physiological medium.

The compositions of the present invention can be suitable for any administration route, such as oral, parenteral, nasal or pulmonary administration. They can be in liquid form, as well as, in solid form as an intimate mixture (for example following spray drying, lyophilisation, etc.). They can be, for example (but not limited to), in a solid dosage form, such as a gelatin capsule for oral administration, or formulated for nasal or pulmonary inhalation. Other pharmaceutically acceptable dosage forms could be employed such as suspension, emulsion, microemulsion, micronised powder, solution, suppository, pessary, microsphere, nanosphere, implant, etc, whereby the absorption or stability of the peptide drug is improved by the combination with the non-ionic hydrotropic agent. Oral microemulsions are particularly preferred administrations forms.

Therefore, the compositions of the present invention can also be lyophilized and reconstitutable and further comprise one or more stabilising agents, as well as one or more pharmaceutically acceptable excipients.

Exemplary composition ranges for an injectable composition are the following:

antide or hGRF	0.1 - 20.0 mg
nicotinamide	10 - 300 mg

-7-

propylene glycol 0 - 800 mg

Aqueous phase, q.s. 1.0 ml.

The term "peptide", as used in this application, means any compound made up of two or more amino acids. In it, the amino ( $\text{NH}_2$ ) group of one amino acid joins the 5 carboxyl ( $\text{COOH}$ ) group of another, forming a peptide bond. Such amino acids can be naturally occurring, chemically synthesised or modified. The peptides according to the invention have generally up to 100 amino acids, preferably up to 50, more preferably up to 20.

The wording "poorly soluble in aqueous physiological saline solution", as used in 10 the present application, means that in such a solution, at room temperature without the addition of acids or bases, the peptide shows a solubility  $<1$  mg/ml and/or that the solubility in aqueous physiological saline solution is one order of magnitude lower than the solubility in water alone under the same conditions.

The invention will now be described by means of the following Examples, which 15 should not be construed as in any way limiting the present invention. The Examples will refer to the Figure specified here below.

#### BRIEF DESCRIPTION OF THE DRAWING

Figure 1: The antide solubility in 0.9% NaCl solution versus nicotinamide concentration 20 is reported. The semi logarithmic plot shows that the solubility of antide bears a logarithmic relationship with the concentration of nicotinamide present. The linear nature of this profile is important, as it allows dilution effects to be considered accurately and also shows that an equilibrium solubility has been reached for the drug in these solutions.

#### EXAMPLES

##### **Materials**

Antide bulk (Bachem), batches 8901 and 9001

hGRF(1-29)-NH<sub>2</sub> (Bachem), batches 1299201 and 1299202

Dulbecco's phosphate buffered saline (Sigma, D-8537)

30 Histidine hydrochloride (Merck, 1.04351 - Biochemistry grade),

Nicotinamide (Fluka, 72345), USP grade,

-8-

Phenylalanine (Merck, 7256) - Biochemistry grade.

Sodium benzoate (Merck, 6290), Ph.Eur/NF grade.

Sodium salicylate (Sigma, S-3007) - General Purpose Reagent, 35H1207.

Thiamine hydrochloride (Merck 8181) - Biochemistry grade.

5 Rubber stoppers, butyl rubber (Pharmagummi, art. 1779 W1816 grey)

3 ml vials DIN2R glass type I (Nuova Ompi)

All the other reagents used were "Analytical grade", unless otherwise specified.

#### Equipment

The following equipment was used:

10 • Merck Hitachi HPLC system (L-6200 Pump, L-4250 Detector, AS-2000A

Autosampler, Compaq PC, HPLC-Manager 2000 software)

• Waters HPLC system (626 Pump, 600S Controller, 994 Detector, 717 Autosampler, NEC PC, Maxima Baseline software)

• Freeze-dryer (Edwards, Lyoflex mod. 06 and mod. 04)

15

#### Analytical method for antide

RP-HPLC gradient elution, C-18 (e.g. Vydac 218 TP54, 250 x 4.6 mm) column.

UV detection at 215 nm, injection volume 15 µl, mobile phase A: pH 4.5 phosphate buffer (0.1M), mobile phase B: acetonitrile, flow rate = 1.0 ml/min, runtime = 23 min.

20 External standard solution concentrations of 100 µg/ml were injected during analysis.

The gradient was: 77% A, 23% B to 52% A, 48% B over 30 min.

#### Analytical method for hGRF

A RP-HPLC method has been developed for the analysis of GRF(1-29)-NH<sub>2</sub>

25 which is capable of differentiating the following degradation products:

Oxidised: at Met<sup>27</sup>

Free acid: GRF(1-29)OH

Desamido: α-Asp<sup>8</sup>, β-Asp<sup>8</sup> and succinimidyl-Asn<sup>8</sup>

Acetylated: acetyl Tyr<sup>1</sup>

30 Isomerised: β-Asp<sup>3</sup> and succinimidyl-Asp<sup>3</sup>

Truncated: hGRF(4-29)-NH<sub>2</sub>, GRF(9-29)-NH<sub>2</sub>.

-9-

This method has been used to determine the chemical purity of a number of solutions of hGRF, during storage at 4° and 40 °C as demonstrated in the following tables.

Conditions were similar to those for antide, using a mobile phase composed of 5 ACN/H<sub>2</sub>O and with TFA in place of phosphate buffer. The gradient operated over a period of 60 minutes, with a total run time of 80 minutes.

#### **Antide stability in aqueous solutions**

Preliminary stability testing of 0.1 mg/ml antide solutions at -20°C, 4°C, 25°C 10 and 40°C was performed to evaluate their stability at pH 2, 3 and 4. The solutions at 0.1 mg/ml were prepared dissolving antide in water and adjusting the pH using 0.01 M hydrochloric acid.

#### **hGRF stability in aqueous solutions**

15 Stability testing of 2.0 mg/ml, 5.0 mg/ml and 10.0 mg/ml hGRF aqueous solutions at 4°C and 40 °C, incorporating nicotinamide was performed to evaluate their stability at pH 7.5. The effect of the addition of propylene glycol has also been evaluated.

#### **20 Solubilisation studies for antide**

Solubilisation studies were carried out to study the effect of:

- pH (solutions were acidified with either acetic acid or hydrochloric acid)
- hydrotropic agents (nicotinamide, sodium saccharin, sodium salicylate, sodium benzoate, histidine hydrochloride, thiamine hydrochloride, phenylalanine).

25 Saline used in these studies corresponds to 0.9% sodium chloride solution.

Based on the results of previous studies, excess antide was added to the test solution and observed visually to evaluate the solubility following equilibration overnight at 25°C. Following the visual analysis, a number of solutions were selected for further quantitative determination of the solubility by filtration (0.45 µm filters) and appropriate 30 dilution using the RP-HPLC method described above.

-10-

### **Solubilisation studies for hGRF**

Solubilisation studies were carried out to study the effect of saline and pH 7 phosphate buffer on the solubility of hGRF.

5 Quantitation of the amount of hGRF dissolved was performed by filtration of the equilibrated solution through a 0.45 µm filter prior to dilution and analysis by HPLC.

### **Manufacturing of antide freeze dried formulation**

50 vials of antide/nicotinamide freeze-dried product are manufactured as follows:

1) weigh 0.7 g antide acetate (expressed as dry powder), weigh 3.5 g mannitol and add about 50  
10 ml water for injectables (WFI)

2) bring both materials into solution by gentle stirring

3) bring to final weight of 70 g with WFI

4) fill the vials with 1 ml of solution

5) freeze-drying cycle:

15 Load the product at room temperature.

Bring the product to -40°C and maintain for 1.5 hours, then apply vacuum.

Perform primary drying for 2 hours.

Raise the shelf temperature to +20°C and maintain for 16 hours.

Raise the shelf temperature to +40°C and maintain for 5 hours to complete.

20

### **Results and discussion**

#### **Antide stability in aqueous solutions**

Three month stability testing of 0.1 mg/ml antide solutions at pH 2, 3 and 4, adjusted using diluted hydrochloric acid and stored at -20°C, +4°C, +25°C and +40°C is shown in Tables 1 & 2. The percentage of degradation increased as the pH decreased as defined by the purity values observed. It was also seen that storage at -20°C negatively affected the stability of the product when the pH was lower than 4.

### **Solubilisation studies for antide**

30 **Effect of pH**

- 11 -

Tables 3 to 7 summarise the observations collected in order to obtain information on the solubility behaviour of antide in water for injectables (WFI), WFI acidified by HCl or acetic acid, saline and saline acidified by acetic acid. In agreement with previous studies, the solubility of antide increased as the pH decreased.

5 In Table 3, the natural pH of antide acetate in solution is from 4.4 to 5.0, depending on the amount dissolved. Antide could be dissolved easily in water at a concentration of 1.0 mg/ml, however, without further acidification the solubility limit was found to be 8.1 mg/ml. The pH was not measured when the solution had gelled.

10 When antide was added at 50 mg/ml to water adjusted to pH 3.0 with hydrochloric acid, a gel formed, indicating partial solubility. On the basis of these results, it would be necessary to add further acid in order to fully solubilise a solution at this concentration.

15 Tables 4 and 5 show that significant amounts of acetic acid did not effectively solubilise antide in water. The addition of 2% acetic acid in water which equates to 0.33 M solution, (deemed too concentrated for injectable purposes) was found to effectively solubilise between 10 and 20 mg/ml of antide.

The addition of 5 mg/ml antide to 1% acetic acid gave a solution of pH 3.12 in the presence of saline. The solution remained opalescent, indicating that the drug solubility was less than 5 mg/ml; the exact amount was not quantified (Table 6).

20 Table 7 shows that antide at a concentration of 10 mg/ml in saline is not soluble at a pH of 3.0 or 4.6, using 4% acetic acid to achieve the reduction in pH. The pH was measured when the solution was prepared, after which the gel gradually formed indicating the partial solubility of the drug. At pH 3.0 the solubility of the drug in saline solution was found to be 2.2 mg/ml, compared to the value of 0.025 mg/ml at the natural pH of 5.04 for this solution.

#### Effect of hydroscopic solubilising agents on antide solubility

The effect of different hydroscopic agents (1.5% & 15% w/w) in saline solutions was also evaluated and is described in Tables 8 and 9. Nicotinamide and thiamine hydrochloride proved to be the most effective solubilising agents.

-12-

Table 8 shows the effect of low concentrations (1.5% w/w) of the hydrotropic agents selected on the pH of the solution as measured before drug addition, however, they were not effective in solubilising antide at a level of 10 mg/ml in saline.

The experiment described in Table 8 was repeated using a lower concentration of 5 drug and a higher concentration of hydrotropic agent as described in Table 9. On quantifying the amount of antide dissolved, it was found that nicotinamide was a very good solubilising agent for antide, with 3.3 mg/ml dissolved in 15% w/w nicotinamide/saline solution at pH 5.8. Thiamine hydrochloride also solubilised significant amounts of antide in saline, with 3.0 mg/ml dissolved in 15% w/w saline 10 solution. In this case, however, the acidification caused by the acid salt of thiamine caused a substantial reduction of pH to 3.3 and the solubilising power was largely due to the acidity of this solution. Ionic hydrotropic agents did not result in good solubilisation of antide in saline.

#### Nicotinamide

15 Further investigations were carried out to confirm the solubilising effect of nicotinamide on antide in saline solution and to establish the most effective concentration to use. The effect of the concentration of nicotinamide on antide solubility is shown in Table 10, where it was found that 20% nicotinamide in saline allows the solubilisation of 8.5 mg/ml antide.

20 These results are shown graphically in Figure 1. The semi logarithmic plot shows that the solubility of antide bears a logarithmic relationship with the concentration of nicotinamide present. The linear nature of this profile is important as it allows dilution effects to be considered accurately and also shows that an equilibrium solubility has been reached for the drug in these solutions.

25 Since nicotinamide proved to be a very good solubilising agent for antide, a further study was undertaken to verify the chemical compatibility between nicotinamide and antide. Four formulations of antide and nicotinamide at different concentration ratios and adjusted to pH 5 were prepared and tested over 3 months at +40°C, +25°C and +4°C. The stability data are reported in Table 11.

30 An increased viscosity with precipitate formation was observed in the formulation containing 10 mg/ml antide and 5% nicotinamide after 1 week at +40°C and +25°C; no

-13-

change was observed in the samples stored at +4°C. This indicated that the solubility of antide in nicotinamide/saline solutions diminished as the temperature rose. No chemical degradation was observed in the formulations after 3 months, indicating that no chemical incompatibility existed between the two substances at the investigated ratios.

5 Chromatographic traces of antide were identical to those of the standard, with the addition of the early eluting nicotinamide peak which appeared at a retention time of 3.2 minutes.

The amounts of nicotinamide required to solubilise antide following injection may be greater than the isotonic concentration of nicotinamide which is 4.5%. Therefore, 10 following injection at an extravascular site, the body fluids would re-equilibrate to adjust the osmotic balance, resulting in a dilution of the solubilising agent. In an effort to simulate the potential dilution of an injected formulation that could occur, the effect of diluting formulations containing antide and nicotinamide in phosphate buffered solution (PBS) was studied by the following in-vitro experiments. The dilutions were made to 15 bring the nicotinamide concentration to 5% following the addition of PBS. Solutions of antide at concentrations from 1 to 5 mg/ml were prepared in 15% nicotinamide/WFI, followed by dilution in PBS by a factor of 3. Observations were performed over a period of 3 hours, with the effect of the dilution in PBS shown in Table 12.

The results are in good agreement with the measured solubility of antide in these 20 systems, reported in Table 10 where a solution of 5% nicotinamide in saline can solubilise about 0.5 mg/ml of antide. The data shows that it is possible to produce a slightly supersaturated solution of antide in the body fluids by preparing, e.g. a 2 mg/ml solution of antide in 15% nicotinamide. On dilution to 5% this would contain 0.67 mg/ml of antide which remained in solution during the studies reported above.

25 Therefore, suitable formulations containing for example 15% nicotinamide and 2 mg/ml of antide or 5% nicotinamide and 0.5 mg/ml of antide may reduce precipitation at the injection site after administration. Other suitable formulations, such as those described above, can be determined from the solubility profiles in Figure 1 and are preferred in accordance with this invention.

30 As a result of the Examples above, antide can be effectively solubilised by a number of agents which are non-ionic aromatic hydrotropic compounds, while the

-14-

addition of ionised species reduces the aqueous solubility. Antide solubility is shown to increase with decreasing pH, while the chemical stability of antide decreases as the pH is reduced below the value of pH 4.

It is also found that antide remains chemically stable in the presence of  
5 nicotinamide.

### Solubilisation studies for hGRF

The solubility of hGRF was measured at 25°C in water versus saline (stored for one week to reach equilibrium) and PBS stored for 5 days. The solubilities were

10	WFI	> 1 mg/ml
	0.9% NaCl	0.042 mg/ml
	PBS	0.032 mg/ml

After storage at 40 °C for one week, the following solubilities were observed:

15	0.9% NaCl	0.097 mg/ml
	0.9% NaCl + 5% nicotinamide	0.875 mg/ml

hGRF solutions (5 and 20 mg/ml) were prepared in water adjusted to pH 3.0 and 5% or 20% nicotinamide added. By increasing the pH, the point of hGRF precipitation was determined. The results demonstrate the ability of nicotinamide to solubilise hGRF even at high pH. The results are reported in Table 13.

20

### hGRF stability in aqueous solutions

By incorporating nicotinamide into aqueous solutions of hGRF, it has been discovered that this agent also has the ability to dramatically reduce the chemical degradation of this peptide. GRF is known to degrade rapidly through deamidation in 25 aqueous solution, the rate of which is increased by increasing the pH above the 4 - 5 region. Aqueous solutions of hGRF were prepared in water adjusted to pH 7.5, containing either 0, 5 or 20% nicotinamide and stored for up to 12 weeks at 4° and 40°C.

The data presented in Tables 14 and 15 show that the rate of deamidation is substantially reduced by the presence of nicotinamide, particularly the rate of deamidation at the asparagine at position 8 in hGRF, with solutions more stable at the lower temperature.

-15-

Since deamidation occurs in solution, the activity of water is an important factor governing the rate of degradation. Therefore, since hGRF is soluble in propylene glycol, the stability of hGRF in solution in this solvent was studied in order to understand the effect on deamidation reactions.

5 The data presented in Tables 16 and 17 demonstrate that degradation via deamidation at the asparagine at position 8 was reduced to a very low level in this solution. The data also show that hGRF dissolved in propylene glycol shows substantial degradation via routes which have not as yet been fully determined, with numerous new degradation products forming as peaks eluting after the main peak for hGRF under the 10 chromatographic conditions employed.

It can be seen clearly from the data that the addition of nicotinamide to the solution of hGRF in propylene glycol causes a substantial reduction in the level of these degradation products. The rates of degradation were again affected by temperature with the solutions at 4 °C being more stable than at 40 °C.

15 To evaluate the effect of combining both nicotinamide and propylene glycol in an aqueous solution of hGRF, 10 mg of hGRF was dissolved in a solution containing 60% propylene glycol and 20% nicotinamide, made up to volume with water adjusted to pH 7.5.

20 The data presented in Tables 18, 19 and 20 demonstrate that degradation via deamidation at the asparagine at position 8 was reduced to a very low level in this solution and at 4 °C the rate of degradation was sufficiently low to be considered for pharmaceutical applications.

25 These data show the stabilisation of aqueous solutions of hGRF by the use of nicotinamide and incorporating propylene glycol. It is considered that for different pharmaceutical applications the composition could be optimised or that other non-aqueous solvents could be employed to reduce the activity of water.

However, the stabilising actions of nicotinamide are necessary for effective pharmaceutical performance.

-16-

TABLE 1

Stability of 0.1 mg/ml antide solutions at pH 2, 3 and 4; Temp= +4° and -20°C

Formuln.	Test	T=0	-20°C		+4°C	
			5W	5W	12W	12W
pH=2						
	Purity (%)	99.60	87.50	98.80	98.20	
pH=3						
	Purity (%)	99.60	93.50	99.40	99.10	
pH=4						
	Purity (%)	99.50	99.30	99.2	99.20	

5

TABLE 2

Stability of 0.1 mg/ml antide solutions at pH 2, 3 and 4; Temp= +25° and +40°C

Formuln.	Test	T=0	+25°C		+40°C	
			5W	12W	5W	12W
pH=2						
	purity (%)	99.6	95.8	92.0	83.4	65.0
pH=3						
	Purity (%)	99.6	99.0	98.8	97.7	95.6
pH=4						
	Purity (%)	99.5	99.6	99.4	99.4	99.1

-17-

**TABLE 3**  
**antide solubility in WFI**

antide (nominal amount added, mg/ml)	Appearance	pH	Solubility (mg/ml)
50	gel	ND	ND
10	opalescent	4.40	8.13
1	clear	5.00	1.00

5

**TABLE 4**  
**antide solubility in WFI + 4% acetic acid**

antide (nominal amount added, mg/ml)	Appearance	pH
100	gel	ND
50	gel	ND
33	gel	ND
25	opalescent	3.18

10

**TABLE 5**  
**antide solubility in WFI + 2% acetic acid**

antide (nominal amount added, mg/ml)	Appearance	pH
40	gel	ND
20	opalescent	3.31
10	clear	3.31

-18-

**TABLE 6**  
**antide solubility in saline + 1% acetic acid**

antide (nominal amount added, mg/ml)	Appearance	pH
10	gel	ND
5	opalescent	3.12

5

**TABLE 7**  
**Effect of pH on antide solubility in saline**

antide (nominal amount added, mg/ml)	pH	Appearance	Solubility (mg/ml)
1	5.04	opalescent	0.025
10	4.61	gel	ND
10	3.01	opalescent	2.23

10

**TABLE 8**  
**Effect of 1.5% hydrotropic agents on antide solubility in saline**

antide (nominal amount added, mg/ml)	Hydrotropic agent	pH	Appearance	Solubility (mg/ml)
10	nicotinamide	4.89	gel	ND
10	saccharin	4.61	gel	ND
10	sodium salicylate	5.08	gel	ND
10	thiamine hydrochloride	3.94	gel	ND

-19-

**TABLE 9**  
**Effect of 15% hydrotropic agents on antide solubility in saline**

antide (nominal amount added, mg/ml)	Hydrotropic agent	pH	Appearance	Solubility (mg/ml)
5	nicotinamide	5.79	opalescent	3.32
5	sodium salicylate	5.81	opalescent	0.21
5	thiamine hydrochloride	3.30	opalescent	3.01
5	sodium benzoate	6.69	opalescent	0.072
5	histidine hydrochloride (5%)	4.17	opalescent	0.076
5	phenylalanine (1.7%)	4.59	opalescent	0.066

5

**TABLE 10**  
**Effect of nicotinamide concentration on antide solubility in saline**

antide (nominal amount added, mg/ml)	Nicotinamide (%)	pH	Appearance	Solubility (mg/ml)
1	5	ND	opalescent	0.47
5	10	5.68	opalescent	1.40
5	15	5.76	opalescent	3.23
10	20	5.64	opalescent	8.49

-20-

**TABLE 11**  
**Stability of nicotinamide/antide formulations at 4°, 25° and 40°C.**

antide (mg/ml)	Nicotinamide (%)	T=0	+4°C			+25°C			+40°C		
			1W	4W	12W	1W	4W	12W	1W	4W	12W
1	5	1.0	ND	0.9	1.0	0.9	0.9	1.0	1.0	0.9	1.0
1	25	1.0	ND	1.0	1.1	1.0	1.0	1.1	1.0	1.0	1.1
10	5	9.7	10.3	10.0	10.5	gel	gel	gel	gel	gel	gel
10	25	9.8	ND	10.1	ND	9.8	9.5	11.1	10.7	9.4	10.2

5

**TABLE 12**  
**Effect of 1:3 dilution of antide/15% w/w nicotinamide solutions in PBS**

	Ant. 5mg/ml nic. 15%	Ant. 4mg/ml nic. 15%	Ant. 3mg/ml nic. 15%	Ant. 2mg/ml nic. 15%	Ant. 1mg/ml nic. 15%
Time (min)	Dilution 1:3 (PBS)				
0	opalescent	opalescent	clear	clear	clear
5	precipitate	precipitate	clear	clear	clear
15	precipitate	precipitate	opalescent	clear	clear
30	precipitate	precipitate	precipitate	clear	clear
60	precipitate	precipitate	precipitate	clear	clear
120	precipitate	precipitate	precipitate	clear	clear
180	precipitate	precipitate	precipitate	clear	clear

10

-21-  
TABLE 13

**hGRF solubility in aqueous nicotinamide solutions**

Solutions	Initial pH	Precipitation point (pH)
GRF (5 mg/ml in H <sub>2</sub> O at pH 3)	4.93	10.09
GRF (20 mg/ml in H <sub>2</sub> O at pH 3)	4.94	7.20
GRF (5 mg/ml in H <sub>2</sub> O at pH 3 + 5% nicotinamide)	5.65	12.28
GRF (20 mg/ml in H <sub>2</sub> O at pH 3 + 5% nicotinamide)	5.30	10.10
GRF (5 mg/ml in H <sub>2</sub> O at pH 3 + 20% nicotinamide)	6.76	12.01
GRF (20 mg/ml in H <sub>2</sub> O at pH 3 + 20% nicotinamide)	5.52	12.38

*Legend (for the abbreviations in Tables 1-13):*

ND = not determined; W = weeks; Temp = temperature; WFI = water for injectables,  
Ant. = antidi, nic. = nicotinamide

**TABLE 14**

**Stability at +40 °C for GRF (2 mg/ml) + nicotinamide solutions adjusted to pH 7.5**

10

1 WEEK		Chromatographic peak areas (%). In order of elution.					
% Nicotinamide	rtr= 0.76	β-Asp8	β-Asp3	Succ-N8 ?	GRF1-29	Succ-D3 + Asp8	
0	0.8	16.7	3.8	0.3	68.0	nr	5.2
5	0.5	13.4	3.5	0.3	73.9	0.9	3.9
20	0.5	11.5	3.6	0.3	77.1	0.9	3.1
4 WEEKS		Chromatographic peak areas (%).					
% Nicotinamide	rtr= 0.76	β-Asp8	β-Asp3	Succ-N8 ?	GRF1-29	Succ-D3 ? + Asp8	
0	6.2	37.8	5.7	2.7	22.2	2.9	10.4
5	4.9	33.3	6.4	1.9	31.5	2.4	9.0
20	4.2	28.6	7.5	2.1	39.5	2.6	7.6

-22-

TABLE 15

Stability at +4 °C for hGRF (2 mg/ml) + nicotinamide solutions adjusted to pH 7.5

5

% Nicotinamide	Chromatographic peak areas (%). In order of elution.					
	4-29?	β-Asp <sup>8</sup>	β-Asp <sup>3</sup>	Succ-N8 ?	GRF1-29	Succ-D3 ? + Asp <sup>8</sup>
Time zero *	0.1	0.2	0	0.3	97.6	nr 0.6
4 WEEKS						
0	0	1.4	0.1	0.1	95.4	nr 0.8
5	0	0.9	0.1	0	96.8	nr 0.6
20	0	0.8	0.1	0	97.4	nr 0.6
8 WEEKS						
0	0	2.4	0.2	0.1	93.2	nr 1.1
5	0	1.5	0.2	0.1	95.8	nr 0.9
20	0	1.4	0.2	0.1	96.3	nr 0.8
12 WEEKS						
0	1.06	3.39	0.27	0.07	89.9	nr 1.29
5	0.28	2.12	0.26	0.11	94.0	nr 0.97
20	0.15	1.95	0.26	0.10	95.1	nr 0.97

*Legend (for the abbreviations in the Tables 14-15):*nr = not resolved. The Succ-D3 + Asp<sup>8</sup> may elute as an overlapping peak

? = further characterisation is necessary to confirm peak identity

10 rtr = retention time ratio

-23-  
**TABLE 16**

**Stability at +4 °C for hGRF (5 mg/ml) in propylene glycol + nicotinamide solutions  
adjusted to pH 7.5**

5

1 WEEK 4 °C		Chromatographic peak areas (%). In order of elution.						
% Nicotinamide	Met-Ox	β-Asp <sup>8</sup>	Succ-N8	1-29OH	GRF1-29	Succ-D3 + Asp <sup>8</sup>	rtr 1.07	
bulk 1299201	0.04	0	0.6	0.3	97.7	0.4	0.4	0
0	0.2	0	0.2	0.4	95.4	0.5	1.0	-
20	0.3	0	0.4	0.4	97.5	0.4	0.7	-
1 WEEK 4 °C		Chromatographic peak areas (%). In order of elution.						
(Continued)	rtr 1.08	rtr 1.11	rtr 1.13	rtr 1.17	rtr 1.18	rtr 1.20	rtr 1.23	rtr 1.39
0	0.2	0.2	0.4	-	-	0.9	0.4	0.1
20	-	-	-	-	0.3	0.2	-	0.2
4 WEEKS 4 °C		Chromatographic peak areas (%). In order of elution.						
% Nicotinamide	Met-Ox	β-Asp <sup>8</sup>	Succ-N8	1-29OH	GRF1-29	Succ-D3 + Asp <sup>8</sup>	rtr 1.07	
0	0.1	0	0.2	0.3	95.0	0.4	0.9	0.4
20	0.4	0	0.3	0.3	97.1	0.4	1.0	0.1
4 WEEKS 4 °C		Chromatographic peak areas (%). In order of elution.						
(Continued)	rtr 1.08	rtr 1.11	rtr 1.13	rtr 1.17	rtr 1.18	rtr 1.20	rtr 1.23	rtr 1.36
0	0.2	0.6	-	1.6	-	0.3	-	0.1
20	0.1	0.1	-	0.1	-	-	-	0.1
8 WEEKS 4 °C		Chromatographic peak areas (%). In order of elution.						
% Nicotinamide	Met-Ox	β-Asp <sup>8</sup>	Succ-N8	1-29OH	GRF1-29	Succ-D3 + Asp <sup>8</sup>	rtr 1.07	
0	0.3	0	0.2	0.3	92.2	1.2	nr	0.7
20	0.5	0	0.3	0.3	95.7	1.8	nr	0.1
8 WEEKS 4 °C		Chromatographic peak areas (%). In order of elution.						
(Continued)	rtr 1.10	rtr 1.11	rtr 1.13	rtr 1.17	rtr 1.18	rtr 1.20	rtr 1.23	rtr 1.36
0	0.5	0.9	-	2.6	-	0.5	-	0.1
20	0.1	0.1	-	0.2	-	0.1	-	0.1

-24-

TABLE 17

5  
**Stability at +40 °C for hGRF (5 mg/ml) in propylene glycol + nicotinamide solutions adjusted to pH 7.5**

1 WEEK 40 °C		Chromatographic peak areas (%). In order of elution.						
% Nicotinamide	Met-Ox	β-Asp <sup>8</sup>	Succ-N8	1-29OH	GRF1-29	Succ-D3 + Asp <sup>8</sup>	rtr 1.07	
0	0.3	0	0	0.1	82.9	1.1	1.2	-
20	1.6	0	0.3	0.2	88.0	1.3	1.6	-
1 WEEK 40 °C		Chromatographic peak areas (%). In order of elution.						
(Continued)	rtr 1.08	rtr 1.11	rtr 1.13	rtr 1.17	rtr 1.18	rtr 1.20	rtr 1.23	rtr 1.39
0	0.5	3.2	1.4	0.3	3.9	2.6	1.37	0.3
20	0.3	1.4	0.4	0	1.8	1.0	1.2	0
4 WEEKS 40 °C		Chromatographic peak areas (%). In order of elution.						
% Nicotinamide	Met-Ox	β-Asp <sup>8</sup>	Succ-N8	1-29OH	GRF1-29	Succ-D3 + Asp <sup>8</sup>	rtr 1.07	
0	0.5	0	0	0	44.6	1.7	1.5	15.1
20	10.9	0.9	0	0.4	43.1	1.3	4.2	10.3
4 WEEKS 40 °C		Chromatographic peak areas (%). In order of elution.						
(Continued)	rtr 1.08	rtr 1.11	rtr 1.13	rtr 1.17	rtr 1.18	rtr 1.20	rtr 1.23	others
0	15.3	8.4	1.4	3.4	1.4	2.1	1.2	3.4 (n=8)
20	8.9	4.3	-	2.5	2.0	2.0	0.9	8.4 (n=7)

10  
n = number of additional peaks occurring in chromatogram.

TABLE 18

15  
**Stability at +4 °C for hGRF (10 mg/ml) in 60% propylene glycole + 20% nicotinamide, 20% H<sub>2</sub>O adjusted to pH 7.5**

	Chromatographic peak areas (%)						
	GRF 1-29	Oxidation peaks (%)	4-29 ?	β-Asp8	β-Asp3	Succ-N8	Succ-D3 + Asp8
RT Ratio		0.65 - 0.67	0.87	0.89	0.96	0.98	1.06
T=0	98.17	0.07 - 0.07	-	0.04	-	0.38	0.60
4 WEEKS	97.97	0.06 - 0.07	0.03	0.03	0.03	0.28	0.84
8 WEEKS	97.97	0.07 - 0.11	0.03	0.04	0.03	0.21	0.93
12 WEEKS	97.62	0.07 - 0.07	0.08	0.06	0.09	0.16	0.93

-25-

TABLE 19

Stability at +25 °C for hGRF (10 mg/ml) in 60% propylene glycole + 20%  
nicotinamide, 20% H<sub>2</sub>O adjusted to pH 7.5

5

	Chromatographic peak areas (%)						
	GRF 1-29	Oxidation peaks (%)	4-29 ?	β-Asp8	β-Asp3	Succ-N8	Succ-D3 + Asp8
RT Ratio		0.65 - 0.67	0.87	0.89	0.96	0.98	1.06
T=0	98.17	0.07 - 0.07	-	0.04	-	0.38	0.60
4 WEEKS	96.28	0.08 - 0.09	0.03	0.27	0.85	0.15	1.34
8 WEEKS	93.69	0.12 - 0.15	0.03	0.47	2.34	0.08	1.57
12 WEEKS	90.94	0.12 - 0.14	0.10	0.60	3.54	0.10	1.73

10

TABLE 20

Stability at +40 °C for hGRF (10 mg/ml) in 60% propylene glycole + 20%  
nicotinamide, 20% H<sub>2</sub>O adjusted to pH 7.5

15

	Chromatographic peak areas (%)						
	GRF 1-29	Oxidation peaks (%)	r <sub>t</sub> = 0.76	β-Asp8	β-Asp3	Succ-N8	Succ-D3 + Asp8
T=0	98.17	0.07 - 0.07	-	0.04	-	0.38	0.60
4 WEEKS	84.06	0.15 - 0.16	0.22	1.75	8.59	0.10	2.18

(The Succ-D3 + Asp<sup>8</sup> may elute as a single unresolved peak)

-26-

### References

Bongers, J., et al., *Int. J. Peptide. Protein Res.* **39**, 364-374, 1992;

Cannon I.B., *J. Pharm. Sci.* , **84**, 953-958, 1995;

5 Felix A.M. et al., *Peptides*, editors: Giralt E. and Andreu D., pp 732-733, Escom Publishers 1991;

Friedman, A.R. et al., *Int. J. Peptide. Protein Res.*, **37**, 14-20, 1991;

Golightly L., et al., *Med. Toxicol.*, **3**, 128-165, 1988;

Graham C.W. et al. , *Anaesthesia & Analgesia*, **56**, 409-13, 1977;

10 Jain N.K. et al., *The Eastern Pharmacist*, November, 51-54, 1986 Physicians Desk Reference, Librium monograph, 47th Edition, 1993;

Leone Bay A, et al., *J. Med. Chem.*, **39**(13), 2571-2578, 1996;

Maa Y.F. et al., *Int. J. Pharm.*, **140** (2) : 155-168, 1996;

Rasool et al., *J. Pharm. Sci.*, **80**(4), 387 - 393, 1991;

15 Sasaki H., *Biol. Pharm. Bull. (Japan)*, **18/1**, 169-171, 1995;

Serono Symposia USA, *Growth hormone secretagogues*, Chapter 3, editors, B.B. Bercu & R.F. Walker, Springer-Verlag, New York, 1996;

Spiegel A.J. et al., *J. Pharm. Sci.*, **52**, 917-927, 1963;

Wang Y-C.J. et al., *J. Parenter. Drug Assoc.*, **34**, 452-462, 1980;

20 Yalkowsky S .H. et al., *Drug Int. Clin. Pharm.*, **11**, 417-419, 1977;

Yalkowsky S.H. et al., *J. Pharm. Sci.*, **74**, 416-412, 1986.

-27-  
CLAIMS

1. A pharmaceutical composition comprising:
  - a) a peptide poorly soluble in aqueous physiological saline solution, as active ingredient;
  - 5 b) a non-ionic aromatic hydrotropic pharmaceutically acceptable agent; and
  - c) a physiological aqueous solution.
2. The pharmaceutical composition of claim 1, wherein the peptide (a) is an LHRH analogue or a GRF peptide.
- 10 3. The pharmaceutical composition according to any of the preceding claims, wherein the peptide (a) is an LHRH antagonist.
4. The pharmaceutical composition according to any of the preceding claims, 15 wherein the peptide (a) is antide or human GRF.
5. The pharmaceutical composition according to any of the preceding claims, wherein the non-ionic aromatic hydrotropic agent is selected from the group consisting of: nicotinamide, nicotinic acid, benzoic acid, salicylic acid, gentisic acid, ascorbic acid, 20 histidine, tryptophan, phenylalanine, tyrosine, cresol, phenol, xanthines, pyridoxine, folic acid, saccharin, as well as non-ionic derivatives thereof.
6. The pharmaceutical composition according to any of the preceding claims, 25 wherein the non-ionic aromatic hydrotropic agent is nicotinamide.
7. The pharmaceutical composition according to any of the preceding claims, which is lyophilised and reconstitutable and further comprises one or more stabilising agents.
8. The pharmaceutical composition according to any of the preceding claims, 30 which further comprises propylene glycol.

-28-

9. The pharmaceutical composition according to any of the preceding claims, which is suitable for parenteral, oral, nasal or pulmonary administration route.

10. The pharmaceutical composition according to any of the preceding claims,  
5 further comprising one or more pharmaceutically acceptable excipients.

11. The pharmaceutical composition according to any of the preceding claims, which is suitable for injections.

10 12. The pharmaceutical composition of claim 10, which has the following composition ranges:



antide or hGRF 0.1 - 20.0 mg

nicotinamide 10 - 300 mg

propylene glycol 0 - 800 mg

15 Aqueous phase, q.s. 1.0 ml.

1/1

**FIGURE 1****Antide solubility in 0.9% NaCl +  
nicotinamide****Antide solubility in 0.9% NaCl +  
nicotinamide**

# INTERNATIONAL SEARCH REPORT

International Search Report No  
PCT/EP 98/03079

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K38/09 A61K38/25 A61K47/22

According to International Patent Classification(IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 09617 A (NOVONORDISK AS) 11 July 1991 *see in particular claims 1,2,8;p.2 1.26-30 * ---	1,5-7, 9-11
X	US 5 487 898 A (LU MOU-YING F ET AL) 30 January 1996 *see in particular claims 1,2,9,11,13;Table 1-8; examples 3,5 * ---	1-3,5, 9-11
X	EP 0 374 120 A (MONSANTO CO) 20 June 1990 *see in particular claims 1,10; examples 2,7; Table 3; --- -/-	1,2,4,5, 9-11

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

23 September 1998

07/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentstaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Isert, B

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 98/03079

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 517 211 A (TEIKOKU SEIYAKU KK) 9 December 1992 *see in particular claims 1-3,6,11; Examples 7,8; p.4 1.21-26 * ----	1,5,7, 9-11
P,X	EP 0 787 497 A (MITSUI TOATSU CHEMICALS) 6 August 1997 *see claims 1-7; page 7, lines 50-54 * -----	1,5-7, 9-11

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No  
PCT/EP 98/03079

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9109617	A 11-07-1991	AT 122567 T		15-06-1995
		AU 641721 B		30-09-1993
		AU 7047191 A		24-07-1991
		CA 2070814 A		22-06-1991
		DE 69019534 D		22-06-1995
		DE 69019534 T		21-09-1995
		DK 506792 T		09-10-1995
		EP 0506792 A		07-10-1992
		ES 2072596 T		16-07-1995
		US 5382574 A		17-01-1995
US 5487898	A 30-01-1996	US 5284657 A		08-02-1994
		AU 669856 B		27-06-1996
		AU 2519392 A		16-03-1993
		CA 2103163 A		04-03-1993
		EP 0601053 A		15-06-1994
		IL 102857 A		18-02-1997
		JP 6510046 T		10-11-1994
		PT 100812 A		30-09-1993
		WO 9303751 A		04-03-1993
EP 0374120	A 20-06-1990	AU 4617689 A		21-06-1990
		CA 2005226 A		13-06-1990
		CN 1043631 A		11-07-1990
		CZ 8907028 A		18-01-1995
		DK 626089 A		14-06-1990
		JP 2204418 A		14-08-1990
		PT 92548 A		29-06-1990
EP 0517211	A 09-12-1992	AU 653026 B		15-09-1994
		AU 1726492 A		10-12-1992
		CA 2070061 A		08-12-1992
		FI 922579 A		08-12-1992
		JP 5148154 A		15-06-1993
		SG 43858 A		14-11-1997
EP 0787497	A 06-08-1997	AU 686962 B		12-02-1998
		AU 1243397 A		14-08-1997
		CN 1165034 A		19-11-1997